comprehensive -WSS

comprehensive

author：fashion 2025-09-30 07:38:47 - browse：6624

De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke.

He is also trying to fight the long legacy of racism in neuroscience. During 2020, when it was difficult to conduct research, he said, “I got the chance and the ability to read more widely and to just look into the legacy of neuroscience.” He found a direct line from racist pseudoscience like phrenology to disparities in neuroscience today, like how the texture of Black people’s hair can sometimes exclude them from clinical trials because electrodes are not designed for them. In 2021, he co-founded Black in Neuro, an organization dedicated to improving Black representation in neuroscience.

On this episode of the “First Opinion Podcast,” I spoke to him about how the past and present racism in neuroscience could be reflected in the future, especially as neurotechnology like brain implants become more common.

“I’m not saying that whatever electrode that you made or created is racist. But when you have someone who … creates a technology but doesn’t think about the wide range of users that are potentially going to use it, then that’s where the problem comes in,” he told me.

We also discussed the way inequities in neuroscience research are visible in stroke wards, how brain implants might jump from helping disabled people to being used for human enhancement, and more.

Our conversation was inspired by his recent First Opinion essay, “Neuroscience has to grapple with a long legacy of racism if it wants to move into the future.” The book I mention at the end is “Lock In” by John Scalzi, a great sci-fi mystery exploring themes of race, socioeconomic status, neurotechnology, and more.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Histogen: Failed biotech offers rare public look inside

focus

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Was Amgen transparent enough on FDA's concern on cancer drug?

CDC marks new Covid

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

How to bring more disabled researchers into academia

NEJM study link tiny plastics in blood vessels to heart problems

focus

comprehensive

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Colorectal cancer study finds potential in overlooked immune cell

Sports medicine is finally prioritizing gender equality

Chan Zuckerberg Biohub Chicago to focus on inflammation

United colonoscopy coverage change 'may cost lives,' doctors say

Amylyx ALS drug failure raises questions and concerns

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Change Healthcare payments predicted restored March 15

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amylyx ALS drug fails large clinical trial

Wikipedia

FDA authorizes Novavax’s updated Covid

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

How to bring more disabled researchers into academia

First medicine developed to treat MASH expected to be approved soon

leisure time

hotspot

focus

leisure time